Back From The Dead Biodexa Makes Bid For VarianBio - Scrip
| BDRX Stock | 1.41 0.03 2.17% |
Slightly above 52% of Biodexa Pharmaceticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Biodexa Pharmaceticals suggests that many traders are impartial. Biodexa Pharmaceticals' investing sentiment can be driven by a variety of factors including economic data, Biodexa Pharmaceticals' earnings reports, geopolitical events, and overall market trends.
Back From The Dead Biodexa Makes Bid For VarianBio Scrip
Read at news.google.com
 |
Biodexa Pharmaceticals Fundamental Analysis
We analyze Biodexa Pharmaceticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biodexa Pharmaceticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biodexa Pharmaceticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Biodexa Pharmaceticals is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Biodexa Pharmaceticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biodexa Pharmaceticals stock to make a market-neutral strategy. Peer analysis of Biodexa Pharmaceticals could also be used in its relative valuation, which is a method of valuing Biodexa Pharmaceticals by comparing valuation metrics with similar companies.
Peers
Biodexa Pharmaceticals Related Equities
| FMCKO | Federal Home | 2.78 | ||||
| NCMI | National CineMedia | 2.42 | ||||
| SLG | SL Green | 2.24 | ||||
| BXP | Boston Properties | 1.05 | ||||
| PLAY | Dave Busters | 0.24 | ||||
| TFSVF | 24SevenOffice Group | 0.00 | ||||
| TPH | TRI Pointe | 0.94 | ||||
| INVH | Invitation Homes | 0.95 |
Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.